

Nallasivam Palanisamy MPhil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2698167/publications.pdf>

Version: 2024-02-01

204
papers

17,206
citations

18436

62
h-index

14156

128
g-index

224
all docs

224
docs citations

224
times ranked

25079
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature</i> , 2012, 487, 239-243.	13.7	2,128
2	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. <i>Science</i> , 2008, 322, 1695-1699.	6.0	995
3	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. <i>Nature Biotechnology</i> , 2011, 29, 742-749.	9.4	950
4	Transcriptome sequencing to detect gene fusions in cancer. <i>Nature</i> , 2009, 458, 97-101.	13.7	791
5	The oestrogen receptor alpha-regulated lincRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014, 5, 5383.	5.8	522
6	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , 2010, 16, 793-798.	15.2	436
7	Whole-Genome Cartography of Estrogen Receptor α Binding Sites. <i>PLoS Genetics</i> , 2007, 3, e87.	1.5	400
8	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. <i>Cancer Cell</i> , 2011, 19, 664-678.	7.7	397
9	A common molecular basis for rearrangement disorders on chromosome 22q11. <i>Human Molecular Genetics</i> , 1999, 8, 1157-1167.	1.4	385
10	Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer. <i>Science</i> , 2009, 326, 1230-1230.	6.0	334
11	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 913.	3.8	333
12	Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. <i>Circulation Research</i> , 1993, 73, 1000-1012.	2.0	326
13	Urine <i>TMPRSS2:ERG</i> Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. <i>Science Translational Medicine</i> , 2011, 3, 94ra72.	5.8	313
14	Derivation of Clinically Compliant MSCs from CD105+, CD24 ^{low} Differentiated Human ESCs. <i>Stem Cells</i> , 2007, 25, 425-436.	1.4	303
15	Chimeric transcript discovery by paired-end transcriptome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12353-12358.	3.3	302
16	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. <i>Nature Medicine</i> , 2011, 17, 1646-1651.	15.2	301
17	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. <i>Cancer Research</i> , 2015, 75, 3720-3727.	0.4	276
18	Expressed Pseudogenes in the Transcriptional Landscape of Human Cancers. <i>Cell</i> , 2012, 149, 1622-1634.	13.5	250

#	ARTICLE	IF	CITATIONS
19	HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab. <i>Cancer Research</i> , 2013, 73, 1635-1646.	0.4	213
20	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. <i>Modern Pathology</i> , 2009, 22, 1083-1093.	2.9	209
21	Genomic Loss of <i>miR-486</i> Regulates Tumor Progression and the <i>OLFM4</i> Antiapoptotic Factor in Gastric Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2657-2667.	3.2	200
22	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. <i>Cancer Cell</i> , 2011, 20, 187-199.	7.7	191
23	IRTA1 and IRTA2, Novel Immunoglobulin Superfamily Receptors Expressed in B Cells and Involved in Chromosome 1q21 Abnormalities in B Cell Malignancy. <i>Immunity</i> , 2001, 14, 277-289.	6.6	176
24	Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors. <i>American Journal of Clinical Pathology</i> , 2015, 143, 672-682.	0.4	168
25	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. <i>Genome Research</i> , 2011, 21, 1028-1041.	2.4	166
26	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , 2015, 21, 344-352.	15.2	165
27	Genomic Amplification of the Human Telomerase Gene (TERC) in Pap Smears Predicts the Development of Cervical Cancer. <i>American Journal of Pathology</i> , 2005, 166, 1229-1238.	1.9	147
28	A Fluorescence <i>In situ</i> Hybridization Screen for E26 Transformation-Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 7629-7637.	0.4	139
29	Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. <i>Cancer Research</i> , 2017, 77, 5194-5206.	0.4	139
30	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. <i>Cancer Research</i> , 2017, 77, 74-85.	0.4	137
31	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. <i>Molecular Cell</i> , 2013, 49, 80-93.	4.5	130
32	Tunable Thermal-Sensitive Polymer-Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor Cells. <i>Advanced Materials</i> , 2016, 28, 4891-4897.	11.1	130
33	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. <i>Nature Communications</i> , 2014, 5, 4527.	5.8	129
34	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. <i>Oncotarget</i> , 2012, 3, 1011-1025.	0.8	126
35	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. <i>Nature Communications</i> , 2014, 5, 5893.	5.8	121
36	Novel Chromosomal Abnormalities Identified by Comparative Genomic Hybridization in Parathyroid Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1766-1770.	1.8	117

#	ARTICLE	IF	CITATIONS
37	Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. <i>Carcinogenesis</i> , 2011, 32, 1607-1614.	1.3	115
38	Solitary Fibrous Tumors of the Head and Neck. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1642-1656.	2.1	111
39	RCP is a human breast cancer-promoting gene with Ras-activating function. <i>Journal of Clinical Investigation</i> , 2009, 119, 2171-83.	3.9	107
40	Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. <i>Blood</i> , 2004, 103, 1862-1868.	0.6	96
41	Baculoviral Vector-Mediated Transient and Stable Transgene Expression in Human Embryonic Stem Cells. <i>Stem Cells</i> , 2007, 25, 1055-1061.	1.4	95
42	The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. <i>Oncogene</i> , 2011, 30, 4339-4349.	2.6	95
43	Novel Chromosomal Abnormalities Identified by Comparative Genomic Hybridization in Parathyroid Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1766-1770.	1.8	93
44	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. <i>Modern Pathology</i> , 2009, 22, 1176-1185.	2.9	91
45	ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate. <i>American Journal of Surgical Pathology</i> , 2010, 34, 478-485.	2.1	91
46	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. <i>Cancer Discovery</i> , 2011, 1, 35-43.	7.7	91
47	Antibody-Based Detection of ERG Rearrangements in Prostate Core Biopsies, Including Diagnostically Challenging Cases: ERG Staining in Prostate Core Biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 935-946.	1.2	88
48	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019, 9, 1538-1555.	7.7	88
49	Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). <i>Genome Research</i> , 2007, 17, 828-838.	2.4	86
50	Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. <i>Science Translational Medicine</i> , 2014, 6, 252ra122.	5.8	86
51	Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 49, 52-60.	1.8	84
52	The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. <i>Oncotarget</i> , 2014, 5, 6654-6669.	0.8	82
53	MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. <i>Blood</i> , 2000, 95, 2666-2671.	0.6	81
54	Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. <i>Oncotarget</i> , 2015, 6, 23445-23461.	0.8	80

#	ARTICLE	IF	CITATIONS
55	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. <i>Oncogene</i> , 2010, 29, 5370-5380.	2.6	75
56	MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. <i>Oncogene</i> , 2016, 35, 6330-6340.	2.6	74
57	Correlation of Urine <i>TPRSS2:ERG</i> and <i>PCA3</i> to ERG+ and Total Prostate Cancer Burden. <i>American Journal of Clinical Pathology</i> , 2012, 138, 685-696.	0.4	72
58	Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. <i>Cancer Research</i> , 1998, 58, 4260-3.	0.4	72
59	Activation of NF- κ B by TMRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. <i>Cancer Research</i> , 2011, 71, 1325-1333.	0.4	71
60	Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. <i>Clinical Endocrinology</i> , 2003, 59, 180-189.	1.2	70
61	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. <i>Nature Biotechnology</i> , 2009, 27, 1005-1011.	9.4	69
62	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. <i>Cell Reports</i> , 2016, 17, 2620-2631.	2.9	68
63	Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR 103. <i>Tissue Antigens</i> , 1997, 49, 564-573.	1.0	62
64	Gene Fusions Associated with Recurrent Amplicons Represent a Class of Passenger Aberrations in Breast Cancer. <i>Neoplasia</i> , 2012, 14, 702-IN13.	2.3	60
65	Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene. <i>American Journal of Surgical Pathology</i> , 2017, 41, 287-298.	2.1	60
66	High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 127.	1.7	60
67	Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2002, 33, 114-122.	1.5	59
68	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. <i>Neoplasia</i> , 2012, 14, 905-IN8.	2.3	59
69	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. <i>Nature Communications</i> , 2020, 11, 384.	5.8	56
70	<i>CD44-SLC1A2</i> Gene Fusions in Gastric Cancer. <i>Science Translational Medicine</i> , 2011, 3, 77ra30.	5.8	54
71	The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. <i>Clinical Cancer Research</i> , 2020, 26, 4933-4946.	3.2	53
72	RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. <i>PLoS Genetics</i> , 2016, 12, e1006306.	1.5	52

#	ARTICLE	IF	CITATIONS
73	Clonal Chromosomal Defects in the Molecular Pathogenesis of Refractory Hyperparathyroidism of Uremia. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1490-1498.	3.0	49
74	Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions. <i>Human Pathology</i> , 2016, 58, 152-160.	1.1	48
75	Epigenetic Silencing of miRNA-338-5p and miRNA-421 Drives SPINK1-Positive Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2755-2768.	3.2	48
76	Novel dual-color immunohistochemical methods for detecting ERG/PTEN and ERG/SPINK1 status in prostate carcinoma. <i>Modern Pathology</i> , 2013, 26, 835-848.	2.9	47
77	Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. <i>Cancer Research</i> , 2002, 62, 4089-94.	0.4	46
78	Chromosome classification using dynamic time warping. <i>Pattern Recognition Letters</i> , 2008, 29, 215-222.	2.6	45
79	Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3035-3040.	3.3	44
80	Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers. <i>Clinical Cancer Research</i> , 2021, 27, 2494-2504.	3.2	44
81	HOXB13 G84E-related Familial Prostate Cancers. <i>American Journal of Surgical Pathology</i> , 2014, 38, 615-626.	2.1	41
82	Inherent Signals in Sequencing-Based Chromatin-ImmunoPrecipitation Control Libraries. <i>PLoS ONE</i> , 2009, 4, e5241.	1.1	40
83	Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1098-1109.	1.5	38
84	Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. <i>Oncogene</i> , 2001, 20, 7686-7693.	2.6	37
85	Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization—a correlative study with urine PCA3 and TMPRSS2-ERG. <i>Modern Pathology</i> , 2014, 27, 609-620.	2.9	37
86	Expanded Circulating Tumor Cells from a Patient with ALK- Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 397-402.	0.5	37
87	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. <i>Prostate</i> , 2017, 77, 10-21.	1.2	37
88	Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 288-301.	1.5	35
89	Vitamin D Receptor as a Candidate Tumor-Suppressor Gene in Severe Hyperparathyroidism of Uremia I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 868-872.	1.8	34
90	Usefulness of a Monoclonal ERG/FLI1 Antibody for Immunohistochemical Discrimination of Ewing Family Tumors. <i>American Journal of Clinical Pathology</i> , 2013, 139, 771-779.	0.4	34

#	ARTICLE	IF	CITATIONS
91	Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. <i>Oncotarget</i> , 2015, 6, 14614-14624.	0.8	34
92	Cultured circulating tumor cells and their derived xenografts for personalized oncology. <i>Asian Journal of Urology</i> , 2016, 3, 240-253.	0.5	33
93	Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 831-838.	0.7	32
94	The utility of <i>ETV1</i> , <i>ETV4</i> and <i>ETV5</i> RNA <i>in situ</i> hybridization in the diagnosis of <i>CIC</i> and <i>DUX</i> sarcomas. <i>Histopathology</i> , 2017, 70, 657-663.	1.6	32
95	Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. <i>Head and Neck</i> , 2016, 38, E1646-52.	0.9	31
96	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual <i>ERG/SPINK1</i> immunohistochemistry. <i>Modern Pathology</i> , 2016, 29, 157-165.	2.9	31
97	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA <i>In Situ</i> Hybridization Assay. <i>Clinical Cancer Research</i> , 2017, 23, 5622-5630.	3.2	31
98	Renal cell tumors with clear cell histology and intact <i>VHL</i> and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. <i>Modern Pathology</i> , 2017, 30, 1603-1612.	2.9	30
99	Vitamin D Receptor as a Candidate Tumor-Suppressor Gene in Severe Hyperparathyroidism of Uremia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 868-872.	1.8	30
100	Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. <i>Endocrine</i> , 2013, 44, 489-495.	1.1	29
101	Increased expression of <i>EZH2</i> in Merkel cell carcinoma is associated with disease progression and poorer prognosis. <i>Human Pathology</i> , 2017, 67, 78-84.	1.1	29
102	Neurofilament is superior to cytokeratin 20 in supporting cutaneous origin for neuroendocrine carcinoma. <i>Histopathology</i> , 2019, 74, 504-513.	1.6	27
103	Chromosomal Aberrations in Solid Tumors. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 95, 55-94.	0.9	26
104	At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases. <i>Histopathology</i> , 2014, 65, 144-146.	1.6	26
105	Novel RNA Hybridization Method for the In Situ Detection of <i>ETV1</i> , <i>ETV4</i> , and <i>ETV5</i> Gene Fusions in Prostate Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, e32-e40.	0.6	26
106	Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses. <i>Human Pathology</i> , 2015, 46, 690-697.	1.1	25
107	Wnt receptor Frizzled 8 is a target of <i>ERG</i> in prostate cancer. <i>Prostate</i> , 2018, 78, 1311-1320.	1.2	25
108	Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: a need for reappraisal of grading criteria. <i>Histopathology</i> , 2019, 74, 1081-1087.	1.6	24

#	ARTICLE	IF	CITATIONS
109	MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. <i>Blood</i> , 2000, 95, 2666-71.	0.6	24
110	Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): a target for cancer therapeutic intervention?. <i>Cancer Cell International</i> , 2019, 19, 224.	1.8	23
111	Transcriptional network involving ERG and AR orchestrates Distal-less/ homeobox-1 mediated prostate cancer progression. <i>Nature Communications</i> , 2021, 12, 5325.	5.8	23
112	Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t(12;14)(q23;q32). <i>Oncogene</i> , 2004, 23, 6991-6996.	2.6	22
113	Clear Cell Melanoma: A Cutaneous Clear Cell Malignancy. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1328-1336.	1.2	22
114	A Hierarchical Machine Learning Model to Discover Gleason Grade-Specific Biomarkers in Prostate Cancer. <i>Diagnostics</i> , 2019, 9, 219.	1.3	21
115	Small cell carcinoma in the parotid harboring Merkel cell polyomavirus. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 118, 703-712.	0.2	19
116	Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2117-2125.	1.2	19
117	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , 2020, 39, 4077-4091.	2.6	19
118	Identification of a novel germline SPOC1 mutation in a family with hereditary prostate cancer. <i>Prostate</i> , 2014, 74, 983-990.	1.2	18
119	Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. <i>Modern Pathology</i> , 2020, 33, 1092-1103.	2.9	18
120	BCL8 Is a Novel, Evolutionarily Conserved Human Gene Family Encoding Proteins with Presumptive Protein Kinase A Anchoring Function. <i>Genomics</i> , 2002, 80, 158-165.	1.3	17
121	Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India. <i>Prostate</i> , 2015, 75, 1051-1062.	1.2	17
122	SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 235.e1-235.e10.	0.8	17
123	Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern. <i>Human Pathology</i> , 2017, 62, 175-179.	1.1	15
124	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 989-1002.	2.3	15
125	Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue. <i>Prostate</i> , 2020, 80, 38-50.	1.2	15
126	Gene fusion characterisation of rare aggressive prostate cancer variants: adenoid squamous carcinoma, pleomorphic giant cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. <i>Histopathology</i> , 2020, 77, 890-899.	1.6	15

#	ARTICLE	IF	CITATIONS
127	Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack <i>USP6</i> , <i>ROS1</i> and <i>ETV6</i> gene rearrangements. <i>Histopathology</i> , 2018, 73, 321-326.	1.6	14
128	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent <i>ETV1</i> Amplification. <i>Translational Oncology</i> , 2013, 6, 405-412.	1.7	13
129	Association of <i>ERG/PTEN</i> status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. <i>Medical Oncology</i> , 2018, 35, 152.	1.2	13
130	A Noncoding Variant Near <i>PPP1R3B</i> Promotes Liver Glycogen Storage and MetS, but Protects Against Myocardial Infarction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 372-387.	1.8	12
131	Cornelia de Lange syndrome with ring chromosome 3.. <i>Journal of Medical Genetics</i> , 1990, 27, 405-406.	1.5	11
132	Automated Identification of Chromosome Segments Involved in Translocations by Combining Spectral Karyotyping and Banding Analysis. <i>IEEE Transactions on Systems, Man and Cybernetics, Part A: Systems and Humans</i> , 2008, 38, 1374-1384.	3.4	11
133	Activating mutations of the oncogene <i>EZH2</i> in cutaneous melanoma revealed by next generation sequencing. <i>Human Pathology: Case Reports</i> , 2014, 1, 21-28.	0.2	10
134	A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel <i>NTRK3-SCAPER</i> gene fusion. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 70-75.	0.7	9
135	Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin. <i>American Journal of Dermatopathology</i> , 2016, 38, 744-750.	0.3	8
136	Combined loss of <i>TFF3</i> and <i>PTEN</i> is associated with lethal outcome and overall survival in men with prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1751-1759.	1.2	8
137	Abstract 4707: Discovery and characterization of <i>PCAT-1</i> , a novel lincRNA implicated in prostate cancer tumorigenesis. <i>Cancer Research</i> , 2011, 71, 4707-4707.	0.4	8
138	Chromosomal Translocations in AML: Detection and Prognostic Significance. <i>Cancer Treatment and Research</i> , 2009, 145, 41-58.	0.2	7
139	Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 364-373.	0.6	7
140	Interaction of the Androgen Receptor, <i>ETV1</i> , and <i>PTEN</i> Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. <i>Hormones and Cancer</i> , 2015, 6, 67-86.	4.9	7
141	High Serine-arginine Protein Kinase 1 Expression with <i>PTEN</i> Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival. <i>European Urology Open Science</i> , 2021, 23, 1-8.	0.2	7
142	Enrichment and mutation detection of circulating tumor cells from blood samples. <i>Oncology Reports</i> , 2018, 39, 2537-2544.	1.2	6
143	Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma With Features Mimicking Spindle Cell Lipoma. <i>International Journal of Surgical Pathology</i> , 2020, 28, 336-340.	0.4	6
144	Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. <i>Modern Pathology</i> , 2020, 33, 1791-1801.	2.9	6

#	ARTICLE	IF	CITATIONS
145	A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall. <i>Histology and Histopathology</i> , 2016, 31, 223-30.	0.5	6
146	Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease. <i>European Urology Open Science</i> , 2021, 29, 93-101.	0.2	5
147	Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial1Share senior authorship.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 108.e5-108.e13.	0.8	3
148	A Novel <i>COL1A1-CAMTA1</i> Rearrangement in Cranial Fasciitis. <i>International Journal of Surgical Pathology</i> , 2020, 28, 678-682.	0.4	3
149	Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1701-1709.	1.2	3
150	MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. <i>Blood</i> , 2000, 95, 2666-2671.	0.6	3
151	Introduction to Microarray Technology. , 2019, , 75-85.		2
152	Abstract 2012: Recurrent rearrangements of NAALADL2 in prostate, breast, cervical, head and neck and lung squamous cell carcinoma. , 2020, , .		2
153	Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5019-5019.	0.8	2
154	Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry. <i>Cancers</i> , 2021, 13, 2363.	1.7	1
155	Abstract 2808: Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, , .		1
156	Abstract 5206: Role of CtBP1 as a transcriptional corepressor in prostate cancer.. , 2013, , .		1
157	Whole-Genome Cartography of Estrogen Receptor± Binding Sites. <i>PLoS Genetics</i> , 2005, preprint, e87.	1.5	1
158	Cytogenetic Analysis and Related Techniques in Hematopathology. , 2011, , 81-94.		1
159	Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16038-e16038.	0.8	1
160	Abstract 1332: High Throughput isolation and expansion of circulating tumor cells (CTCs) from Non-small cell lung cancer (NSCLC) patients for personalized treatments. , 2019, , .		1
161	Abstract C128: Reprogramming transcription factors SOX2 and REST modulates SPINK1 expression in governing cellular plasticity in prostate cancer. , 2019, , .		1
162	Mutational Analyses of Connexin 26, Connexin 30 and Connexin 46 as Candidate Tumor Suppressor Genes in Parathyroid Carcinoma. <i>International Journal on Disability and Human Development</i> , 2002, 3, .	0.2	0

#	ARTICLE	IF	CITATIONS
163	937 Concordance of ERG gene rearrangements and ERG protein expression in PIN lesions in prostate needle biopsies. <i>European Urology Supplements</i> , 2012, 11, e937-e937a.	0.1	0
164	TRIP13 enhances DNA repair to promote treatment resistance in cancer. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 118, e183.	0.2	0
165	Abstract B90: Genomic loss of a microRNA leads to overexpression of EZH2 in cancer. , 2008, , .		0
166	Abstract 2214: An integrative approach to reveal driver gene fusions from paired end sequencing data in cancer. , 2010, , .		0
167	Abstract 3929: The role of chromosome architecture in the generation of gene fusions in prostate cancer. , 2010, , .		0
168	Abstract PR1: Genomic discovery of CD44-SLC1A2 gene fusions in gastric cancer. , 2010, , .		0
169	Abstract 2227: Concordance of ERG gene rearrangements and ERG protein expression in low grade PIN lesions in prostate needle biopsies. , 2011, , .		0
170	Abstract 2795: An onco-protein axis linking polycomb repressive complex 2 and polycomb repressive complex 1 through miRNAs in cancer. , 2011, , .		0
171	Abstract 2218: Integrated diagnostic methods for detection of multiple gene rearrangements in prostate cancer tissue specimens. , 2011, , .		0
172	Abstract 4840: DNA methylation patterns and transcript isoform regulation in prostate cancer. , 2011, , .		0
173	Abstract 929: Transcriptome sequencing identifies novel non-coding RNAs associated with prostate cancer progression. , 2011, , .		0
174	Abstract 2155: The origins and functional consequences of ETS gene fusions in prostate cancer. , 2011, , .		0
175	Abstract 953: Mechanistic rationale for inhibition of Poly(ADP-Ribose) Polymerase in ETS gene fusion positive prostate cancer. , 2011, , .		0
176	Abstract 2564: Identification of a novel SPOP missense mutation from targeted next-generation sequencing of men with chromosome 17-q linkage. , 2013, , .		0
177	Abstract 4188: The role of microRNA-101 as a master tumor suppressor in cancer. , 2013, , .		0
178	Abstract 5348: Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. , 2013, , .		0
179	Abstract 2780: Xenografts of human prostate cancer - a genetic profile analysis. , 2013, , .		0
180	Abstract 4216: Novel RNA in situ hybridization method for the detection of ETV1, ETV4 and ETV5 rearrangements in prostate cancer. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
181	Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis. , 2015, , .		0
182	Abstract 1581: A study of pulmonary and peripheral vein blood as sources of circulating tumor cells in early lung cancer. , 2015, , .		0
183	Unraveling tumor heterogeneity in prostate cancer by combined immunohistochemistry and RNA in situ hybridization. Journal of Cytology & Histology, 2016, 07, .	0.1	0
184	Abstract PR07: The landscape of molecular aberrations in pediatric and young adult cancer patients undergoing clinical sequencing for disease management: Novel biological findings from the Peds-MiOncoSeq study. , 2016, , .		0
185	Abstract 2849: RNA-binding protein FXR1 negatively regulates senescence by destabilizing mRNA CDKN1A and stabilizing noncoding RNA telomerase RNA component. , 2016, , .		0
186	Abstract A03: Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research. , 2016, , .		0
187	Abstract 1763: A novel RNAin situhybridization approach highly sensitive for detection of Merkel cell polyomavirus. , 2017, , .		0
188	MPO9-20â€¢THE DISTRIBUTION OF COMEDONECROSIS IN INTRADUCTAL VERSUS INVASIVE PROSTATE CANCER: ANALYSIS FROM A LARGE SINGLE CENTER PROSTATECTOMY SERIES. Journal of Urology, 2019, 201, .	0.2	0
189	Abstract 5225: Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. , 2019, , .		0
190	Abstract 4385: Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1): A target for cancer therapeutic intervention. , 2019, , .		0
191	Abstract 915: Pseudogene-associated recurrent gene fusion in prostate cancer. , 2019, , .		0
192	Abstract 4693: Evaluation of prostate tumor molecular heterogeneity using whole mount radical prostatectomy by dual immunohistochemistry and dual RNAin situhybridization. , 2019, , .		0
193	Abstract 4688: Evaluation of tumor heterogeneity in prostate biopsy samples. , 2019, , .		0
194	Abstract B016: CDK7 inhibition suppresses AR addicted Castration-Resistant Prostate Cancer through MED1 inactivation. , 2019, , .		0
195	Abstract B124: ERG mediated transcriptional regulation ofDLX1homeobox gene represents a novel mechanism underlying prostate cancer progression. , 2019, , .		0
196	Abstract B45: High-throughput label-free isolation and expansion of circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients for personalized treatments. , 2020, , .		0
197	Abstract A113: Comprehensive molecular mapping of prostate cancer- Approaching health disparities in molecular tumor heterogeneity perspective. , 2020, , .		0
198	Abstract 5302: Molecular subtype stratification for prostate cancer from mpMRI and histopathology images using convolutional neural networks and transfer learning. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
199	Abstract 1332: High Throughput isolation and expansion of circulating tumor cells (CTCs) from Non-small cell lung cancer (NSCLC) patients for personalized treatments. , 2019, , .		0
200	Abstract 4385: Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1): A target for cancer therapeutic intervention. , 2019, , .		0
201	Abstract 4688: Evaluation of tumor heterogeneity in prostate biopsy samples. , 2019, , .		0
202	Abstract 4693: Evaluation of prostate tumor molecular heterogeneity using whole mount radical prostatectomy by dual immunohistochemistry and dual RNA <i>in situ</i> hybridization. , 2019, , .		0
203	Abstract 5225: Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. , 2019, , .		0
204	Abstract 915: Pseudogene-associated recurrent gene fusion in prostate cancer. , 2019, , .		0